Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months
Authors:
- B. EjlertsenBEB. Ejlertsen
- H.T MouridsenHMH.T Mouridsen
- B. KristensenBKB. Kristensen
- P. PfeifferPPP. Pfeiffer
- C. RoseCRC. Rose
- D. PedersonDPD. Pederson
- M. OvergaardMOM. Overgaard
- E. SandbergESE. Sandberg
- 1 January 1993
- journal article
- clinical trial
- Published by Elsevier in European Journal of Cancer
- Vol. 29 (4) , 527-531
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- When to randomize?Journal of Clinical Oncology, 1991
- Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancerThe Lancet, 1990
- Microcomputer-assisted univariate survival data analysis using Kaplan-Meier life table estimatorsComputer Methods and Programs in Biomedicine, 1988
- Distant Recurrence in Breast Cancer: Survival expectations and first choice of chemotherapy regimenActa Oncologica, 1988
- Improving the Quality of Life during Chemotherapy for Advanced Breast CancerNew England Journal of Medicine, 1987
- Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized study of CMF vs CMF plus tamoxifenEuropean Journal of Cancer and Clinical Oncology, 1985
- A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer A Cancer and Leukemia Group B studyAmerican Journal of Clinical Oncology, 1984
- IMPACT OF CHEMOTHERAPY ON SURVIVAL IN METASTATIC BREAST CANCERThe Lancet, 1980
- Cancer of the BreastNew England Journal of Medicine, 1980
- Assessment of response to therapy in advanced breast cancer.A project of the programme on clinical oncology of the International Union against Cancer, Geneva, SwitzerlandCancer, 1977